Aurobindo Pharma has received final approval from the US FDA to manufacture and market Levonorgestrel tablets in 1.5 mg strength. The product had an estimated market size of $64 million for the 12 months ended October 2015 according to IMS, Aurobindo Pharma said.
The company’s shares are likely to see buying interest from traders, though analysts will closely watch the development. Aurobindo Pharma currently has a total of 221 ANDA approvals.